Recurrent and refractory non-Hodgkin's lymphoma and multiple myeloma

Clinical trials for Recurrent and refractory non-Hodgkin's lymphoma and multiple myeloma explained in plain language.

Never miss a new study

Get alerted when new Recurrent and refractory non-Hodgkin's lymphoma and multiple myeloma trials appear

Sign up with your email to follow new studies for Recurrent and refractory non-Hodgkin's lymphoma and multiple myeloma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New hope for tough blood cancers: experimental drug HRS-3738 enters human testing

Disease control Ongoing

This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About …

Matched conditions: RECURRENT AND REFRACTORY NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMA

Phase 1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 13:02 UTC

Recurrent and refractory non-Hodgkin's lymphoma and multiple myeloma

Get alerted when new Recurrent and refractory non-Hodgkin's lymphoma and multiple myeloma trials appear

New hope for tough blood cancers: experimental drug HRS-3738 enters human testing